Table 2 Overview of duration of treatment and TEAE profile across cohorts
From: Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
|  | M2698 monotherapy (N = 62) | M2698/trastuzumab (N = 13) | M2698/tamoxifen (N = 26) |
|---|---|---|---|
Duration of M2698 therapy | |||
≤ 6 weeks | 26 (41.9) | 6 (46.2) | 10 (38.5) |
> 6–12 weeks | 16 (25.8) | 1 (7.7) | 5 (19.2) |
> 12 weeks | 20 (32.3) | 6 (46.2) | 11 (42.3) |
Median, weeks (range) | 7.4 (0.86–72.0) | 6.9 (2.0–35.9) | 8.4 (0.1–105.1) |
TEAEs | 61 (98.4%) | 13 (100.0) | 25 (96.2) |
TEAEs, grade ≥ 3 | 36 (58.1%) | 9 (69.2) | 15 (57.7) |
TEAE related to M2698 | 34 (54.8%) | 10 (76.9) | 22 (84.6) |
TEAE related to M2698, grade ≥ 3 | 8 (12.9%) | 3 (23.1) | 5 (19.2) |
TEAE l/t permanent discontinuation of any trial treatment | 6 (9.7%) | 3 (23.1) | 9 (34.6) |
TEAE l/t temporary discontinuation of M2698 | 29 (46.8%) | 6 (46.2) | 11 (42.3) |
Serious TEAEs | 26 (41.9) | 5 (38.5) | 13 (50.0) |
Serious TEAE related to M2698 | 5 (8.1) | 1 (7.7) | 3 (11.5) |
TEAE leading to deatha | 6 (9.7) | 2 (15.4) | 3 (11.5) |